Stockreport

InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904 [Yahoo! Finance]

InflaRx N.V.  (IFRX) 
Last inflarx n.v. earnings: 8/14 04:05 pm Check Earnings Report
PDF InflaRx believes that CSU and HS each have potential addressable markets of 1 billion or more for INF904. The company also believes that INF904 could address meaningful [Read more]